The Japanese pharma giant is investing nearly 300 million euros ($300 million) to build a new production facility for plasma-derived therapies and a new warehouse at its existing Lessines site in Belgium, the company revealed Tuesday during a celebration of the site’s 50th anniversary. Source: Fierce Pharma 13/9/2022